Dimensional Fund Advisors LP Acquires 87,457 Shares of Codexis, Inc. (NASDAQ:CDXS)

Dimensional Fund Advisors LP lifted its holdings in Codexis, Inc. (NASDAQ:CDXS) by 34.5% during the 2nd quarter, Holdings Channel.com reports. The firm owned 340,762 shares of the biotechnology company’s stock after buying an additional 87,457 shares during the period. Dimensional Fund Advisors LP’s holdings in Codexis were worth $1,056,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Los Angeles Capital Management LLC bought a new stake in Codexis during the 2nd quarter worth approximately $54,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Codexis during the 1st quarter worth approximately $97,000. State Board of Administration of Florida Retirement System raised its stake in Codexis by 57.4% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 28,500 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 10,395 shares during the period. SG Americas Securities LLC raised its stake in Codexis by 72.6% during the 2nd quarter. SG Americas Securities LLC now owns 36,677 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 15,425 shares during the period. Finally, American Century Companies Inc. raised its stake in Codexis by 18.9% during the 2nd quarter. American Century Companies Inc. now owns 100,734 shares of the biotechnology company’s stock worth $312,000 after acquiring an additional 16,019 shares during the period. Institutional investors own 78.54% of the company’s stock.

Insider Activity at Codexis

In other news, major shareholder Opaleye Management Inc. bought 1,055,000 shares of Codexis stock in a transaction on Friday, September 20th. The stock was acquired at an average cost of $3.01 per share, for a total transaction of $3,175,550.00. Following the completion of the acquisition, the insider now owns 8,390,000 shares of the company’s stock, valued at $25,253,900. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders bought 1,166,000 shares of company stock worth $3,514,910 over the last three months. 2.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have commented on CDXS. Benchmark cut shares of Codexis from a “buy” rating to a “hold” rating in a research note on Monday, August 19th. Cantor Fitzgerald reiterated an “overweight” rating and set a $11.00 price objective on shares of Codexis in a research report on Friday, September 20th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $8.75.

Codexis Stock Up 6.1 %

Shares of CDXS opened at $3.15 on Friday. The firm has a market capitalization of $223.43 million, a P/E ratio of -2.92 and a beta of 2.08. Codexis, Inc. has a 12-month low of $1.51 and a 12-month high of $4.91. The company has a current ratio of 2.99, a quick ratio of 2.92 and a debt-to-equity ratio of 0.46. The firm has a fifty day moving average price of $2.97 and a 200-day moving average price of $3.15.

Codexis (NASDAQ:CDXS) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.06). The company had revenue of $7.98 million for the quarter, compared to analysts’ expectations of $7.64 million. Codexis had a negative net margin of 125.41% and a negative return on equity of 64.06%. During the same period in the prior year, the firm posted ($0.17) earnings per share. Equities research analysts expect that Codexis, Inc. will post -0.75 earnings per share for the current year.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.